Here are the 10-Q quarterly reports from Revium Recovery Inc (RVRC) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow RVRC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RVRC filings page.
Revium Rx. reported no revenue for the quarter, reflecting its status as a pre‑clinical biopharmaceutical company focused on nano‑medicine platforms, including Nano‑Mupirocin, Nano‑Candesartan and an LPLT vaccine program. For the six months ended June 30, 2026, net loss was $1.47 million, compared with $1.67 million in the prior‑year period.
Cash, cash equivalents and short‑term deposits totaled about $1.5 million as of June 30, 2026, down from higher balances at year‑end, and accumulated deficit reached $26.4 million. Management discloses that these conditions, together with the absence of binding financing commitments, raise substantial doubt about the company’s ability to continue as a going concern. Research and development expenses increased while general and administrative expenses declined, and the company advanced Nano‑Mupirocin toward Phase 1 trials. Management also concluded that disclosure controls and procedures were not effective as of June 30, 2026.
Revium Rx reported a net loss of $725,000 for the quarter ended March 31, 2026, similar to the prior year, as it continues to generate no revenue while funding pre-clinical drug development.
Research and development expenses rose to $473,000, reflecting progress on its Nano-Mupirocin program, while general and administrative costs fell to $266,000 due mainly to lower share-based compensation. Cash, cash equivalents and short-term deposits totaled about $2.1 million, with operating activities using $541,000 of cash in the quarter.
The company reported an accumulated deficit of $25.7 million and explicitly stated that these conditions raise substantial doubt about its ability to continue as a going concern. Management plans to seek additional financing but has no binding commitments. Operations are also exposed to regional geopolitical risks in Israel, and management concluded disclosure controls and procedures are not effective.